

Maastricht Consensus Conference on Thrombosis, 22-24 February 2017

Preliminary programme		
Time	Title	Room
Wednesday 22 February 2017		
07.00 - 08.30	Registration participants	Registrion desk MECC - Lobby
08.30 - 10.00	Plenary session (Topic 1) Pleiotropy of hemostasis and coagulation proteases in the pathogenesis of atherothrombosis Chairmen: Pieter Reitsma, Henri Spronk	Room 0.4/0.5
	Athan Kuliopulos: Protease-Activated Receptors(PAR) in Cardiovascular Diseases.	
	Wolfram Ruf: PAR signaling in macrophages	
	Rory Koenen: Leukocytes and atherothrombosis	
	Lina Badimon: adiposity, inflammation and atherosclerosis	
	Johan Heemskerk: Pleiotropic effects of platelets	
Uli Schotten: Hypercoagulability as substrate for atrial fibrillation		
10.00 - 10.30	Coffee break	Exhibition area - Lobby
10.30 - 11.30	6 workshops	
	Athan Kuliopulos - Room 0.1	
	Wolfram Ruf - Room 0.2	
	Rory Koenen - Room 0.3	
	Lina Badimon - Room 0.6/0.7	
	Johan Heemskerk - Room 0.8	
Uli Schotten - Room 0.9		
11.30 - 12.00	Short break	Exhibition area - Lobby
12.00 - 13.00	Consensus discussion	Room 0.4/0.5
13.00 - 14.00	Lunch	Exhibition area - Lobby
14.00 - 15.30	Plenary session (Topic 2) Target identification and new avenues in atherothrombosis management Chairmen: Nigel Mackman, Paola van der Meijden	Room 0.4/0.5
	Gordon Lowe: coagulation proteins and CVD: what did we know?	
	Philipp Wild: Genetics and CVD risk stratification	
	Thomas Renne: Should we inhibit the contact system?	
	Joost Meijers: Factor XI: the ultimate target for thrombosis prevention?	
	Alisa Wolberg: Transglutaminase activity and clot structure	
Trevor Baglin: any more new anticoagulants?		
15.30 - 16.00	Coffee break	Exhibition area - Lobby
16.00 - 17.00	6 workshops	
	Gordon Lowe - Room 0.1	
	Philipp Wild - Room 0.2	
	Thomas Renne - Room 0.3	
	Joost Meijers - Room 0.6/0.7	
	Alisa Wolberg - Room 0.8	
Trevor Baglin - Room 0.9		
17.00 - 17.30	Short break	Exhibition area - Lobby
17.30 - 18.30	Consensus discussion	Room 0.4/0.5
19.30 - 20.30	Welcome Reception	TBC

Thursday 23 February 2017		
08.30 - 10.00	Plenary session (Topic 3) Optimized antithrombotic management (VKA, NOAC and antiplatelet agents) Chairmen: Harry Buller, Yvonne Henskens	Room 0.4/0.5
	Paul Harrison: Platelet Function in relation to atherothrombosis recurrence?	
	Jur ten Berg: dual or triple therapy: how much, how long?	
	John Eikelboom: Organ Specificity of anticoagulants?	
	Jonathan Douxfils: Towards Individually optimized NOAC therapy?	
	Elaine Hylek: How to handle the risks of anticoagulant therapy?	
Harry Crijns: Anticoagulation in AF: to treat or not to treat, that remains the question!		
10.00 - 10.30	Coffee break	Exhibition area - Lobby
10.30 - 11.30	6 workshops	
	Paul Harrison - Room 0.1	
	Jur ten Berg - Room 0.2	
	John Eikelboom - Room 0.3	
	Jonathan Douxfils - Room 0.6/0.7	
	Elaine Hylek - Room 0.8	
Harry Crijns - Room 0.9		
11.30 - 12.00	Short break	Exhibition area - Lobby

12.00 - 13.00	Consensus discussion	Room 0.4/0.5
13.00 - 14.00	Lunch	
14.00 - 15.30	Plenary session (Topic 4) Thrombus resolution and reperfusion injury in CVD Chairmen: Hugo ten Cate, Arina ten Cate	Room 0.4/0.5
	Allart van der Wal: phenotyping atherothrombosis: determinants of instability	
	Robert Ariens: Platelet-fibrin interactions and clot architecture	
	Heleen van Beusekom: reperfusion injury and the heart.	
	Laurent Mosnier: safe options for limiting brain damage in ischemic stroke?	
	Paul Declerck: new concepts of thrombolysis	
15.30 - 16.00	Coffee break	Exhibition area - Lobby
16.00 - 17.00	6 workshops Allart van der Wal - Room 0.1 Robert Ariens - Room 0.2 Heleen van Beusekom - Room 0.3 Laurent Mosnier - Room 0.6/0.7 Paul Declerck - Room 0.8 Diederik Dippel - Room 0.9	
17.00 - 17.30	Short break	Exhibition area - Lobby
17.30 - 18.30	Consensus discussion	Room 0.4/0.5
19.30	Social Event	TBC

Friday 24 February 2017		
08.30 - 10.30	Plenary session (Topic 5) Plenary session: Hot topics and unsolved clinical issues in atherothrombosis (co-sponsored by ESC) Chairmen: Harry Crijns, Imo Hoefer	Room 0.4/0.5
	Erik Boersma: Biomarkers for Cardiovascular Disease	
	Thomas Muenzel: Endothelial dysfunction in atherothrombosis	
	Paul Evans: Contribution of shear stress to atherothrombosis and embolization	
	Esther Lutgens: Immunecells and cardiovascular disease	
	Benjamin Brenner: Cancer and arterial thromboembolism	
10.30 - 11.00	Coffee break	Exhibition area - Lobby
11.00 - 12.00	Plenary session: Topic 1, 2, 3 & 4	Room 0.4/0.5
12.00 - 13.00	Lunch	Exhibition area - Lobby